Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors
一项针对新型 Bcl-2 家族抑制剂 Navitoclax (ABT-263) 的 I 期研究,旨在评估其在小细胞肺癌和其他实体瘤患者中的疗效。
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2010.31.6208
Gandhi, Leena; Camidge, D Ross; Ribeiro de Oliveira, Moacyr; Bonomi, Philip; Gandara, David; Khaira, Divis; Hann, Christine L; McKeegan, Evelyn M; Litvinovich, Elizabeth; Hemken, Philip M; Dive, Caroline; Enschede, Sari H; Nolan, Cathy; Chiu, Yi-Lin; Busman, Todd; Xiong, Hao; Krivoshik, Andrew P; Humerickhouse, Rod; Shapiro, Geoffrey I; Rudin, Charles M